StocksMedium•9 November 2026•
1 min read
ImmunityBio Stock Falls After Reporting Wider Q3 Loss and Revenue Miss
Key Facts
1ImmunityBio reported a wider quarterly loss for Q3 2026 as revenues missed analyst estimates.
2The company's stock fell despite positive ANKTIVA bladder cancer trial results and regulatory approval in Israel.
ImmunityBio reported a wider quarterly loss for Q3 2026 as revenues missed analyst estimates. Benzinga reported that the company's stock declined following the financial results, which outweighed other operational developments.
The stock price of ImmunityBio fell despite positive ANKTIVA bladder cancer trial results and regulatory approval for the drug in Israel. IBRX closed at $8.64 on November 6, 2026, with the session seeing a low of $7.88 and a high of $8.69.